FibroGen (FGEN) – Corporate News
-
FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD
-
FibroGen (FGEN) Begins LELANTOS-2, a Second Phase 3 Clinical Study of Pamrevlumab for Treatment of DMD
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to FGEN Stock Lookup